Today at our booth
The second day of AACR has been filled with a wealth of exciting research, we have compiled our news highlights below. Take a look at some of our highlights and make sure to let us know your thoughts in the comments below or on social media.
Remember you can find us at booth #4438, or follow our Twitter updates @OncologyCentral.
Tomorrow’s key talk to attend
(April 2, 8:15 AM–10:15 AM, Hall A – Convention Center)
Pembrolizumab demonstrates promise in small-cell lung cancer patients
Keytruda® (pembrolizumab) has demonstrated promising anti-tumor activity in patients with pretreated, advanced-small cell lung cancer (SCLC) according to pooled analysis data from the Phase IB KEYNOTE-028 trial and the Phase II KEYNOTE-158 trial.
Could HDAC inhibition combat anti-PD-1 resistance in melanoma patients?
According to results from the ENCORE 601 Phase Ib/II clinical trial, a combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab (Keytruda®) exhibits clinical responses in melanoma patients who had progressed on prior anti-PD-1 treatment.
LOXO-195 shows promise as therapy for tumors with acquired NTRK resistance
LOXO-195, which targets TRKs, showed signs of clinical activity in patients who had solid tumors that harbored NTRK gene fusions. The study included 20 patients receiving LOXO-195 through the Phase I clinical trial and 11 patients receiving a second-generation TRK-targeted therapeutic through an FDA expanded access single patient protocol.
Gilteritinib improves survival for certain acute myeloid leukemia patients
The ADMIRAL Phase III trial has demonstrated that treatment with the FLT3-targeted therapeutic gilteritinib (Xospata®) improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) harboring a FLT3 mutation compared with standard chemotherapy treatment.
Umbralisib trial results give support for use as a marginal zone lymphoma drug
Early results from the UNITY-NHL Phase II clinical trial show promise for the investigational therapeutic umbralisib as a treatment for relapsed/refractory marginal zone lymphoma. The PI3K-delta inhibitor was highly active and well tolerated in patients with 55% of patients having a partial or complete response after 6 months.
Lynch syndrome vaccine could be on the horizon, preclinical trial suggests
A mouse study has suggested that a vaccine preventative of cancer could be feasible for patients with Lynch syndrome. The researchers demonstrated that as few as four neoantigens could be used to safely elicit an immune response, resulting in reduced intestinal tumors and improved survival in a mouse model.
Best of social media #AACR19
400,000 patients in #clinicaltrials & we’re still trying to identify the best predictive #biomarkers for #immunotherapy in #oncology. 400,000. Let that sink in. #ImmunoOnc #AACR19 https://t.co/t0ctCuaVNb
— Tatiana Prowell, MD (@tmprowell) March 31, 2019
Looking forward to sharing the first data on LOXO-195 (BAY 2731954), a next-generation TRK inhibitor at #AACR19 – see you Monday, 3pm, at the Marcus Auditorium! @AACR @alexdrilon @DavidHongMD @sloan_kettering 1/2 pic.twitter.com/ymNlnMVV83
— David Hyman (@DHymanMD) March 31, 2019
Jim Allison @MDAndersonNews: people tend to say we have 2 checkpoint blockers, one is better tolerated, so let’s use that — but they’re very different #Immunotherapy #AACR19 pic.twitter.com/6HCVGTgitE
— Liz Highleyman (@LizCancerHealth) April 1, 2019